 British American Tobacco has performed well in H1, as its recovery was broad-based. It has also maintained its pricing leadership, underpinning its robust margins. However, BTI remains far below its pre-COVID highs, suggesting that the market has not re-rated it. We assessed that the market remains tentative over its transition strategy. 